A LinkedIn post from Acclaro Medical highlights the addition of advanced practice nurse Jennifer Rummell and her practice, Jenerous Hydration & Wellness, as a new user of the company’s UltraClear laser platform. The post relays Rummell’s rationale for adopting UltraClear, emphasizing its Laser-Coring technology for treating neck, hands, arms, areas above the knees, and the abdomen, as well as its suitability for sensitive skin and younger patients.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also notes Rummell’s comparison of UltraClear with an existing CO2 device, suggesting UltraClear may offer a gentler option that can be used without numbing while remaining tolerable for patients. For investors, this use-case narrative may indicate growing practitioner interest in fiber-based 2,910 nm laser technology and could signal incremental demand drivers in aesthetic practices seeking versatile, comfort-focused skin treatments.
By showcasing adoption in a wellness-focused practice, the content implies potential for broader penetration into medspa and outpatient aesthetics settings beyond traditional dermatology clinics. If replicated across similar practices, this pattern of uptake could contribute to recurring device and consumable revenue, reinforcing Acclaro Medical’s positioning in the competitive energy-based aesthetics equipment segment.